



## Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

## Stock Performance


### NASDAQ: RDHL.US <sup>1</sup>

|             |  |
|-------------|--|
| Last Trade: | 5.24   |
| Trade Time: | 4:00 PM ET<br>Jan 19, 2018                         |
| Change:     | 0.03 <span style="color: green;">↑</span> (0.576%) |
| Volume      | 27,879   |



### TASE: RDHL <sup>1</sup>

|             |  |
|-------------|--|
| Last Trade: | 177.00   |
| Trade Time: | 4:24 PM IT<br>Jan 21, 2018                         |
| Change:     | 1.20 <span style="color: green;">↑</span> (0.683%) |
| Volume      | 88,274   |



## Press Releases [\[ View all \]](#)

Jan 17, 2018

[RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam® to Savings Program for Uninsured or Underinsured Patients](#)

Jan 16, 2018

[RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA® for IBS-D](#)

Dec 22, 2017

[RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 \(YELIVA®\) for Cholangiocarcinoma at Mayo Clinic and MD Anderson](#)

## Events [\[ View all \]](#)

Feb 12–13, 2018

[BIO CEO & Investor Conference](#)

Mar 12–14, 2018

[BIO-Europe Spring 2018](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

## RedHill Biopharma Ltd

Investor Relations Department  
21 Haarbaa St  
Tel Aviv 64739  
Israel

Visit IR website [↗](#)

Sign-up for email alerts [↗](#)

